The DOI matches its Crossref record.
Hypericin - The Facts About a Controversial Agent
Abstract
Hypericin is a naturally occurring substance found in the common St. John's Wort (Hypericum species) and can also be synthesized from the anthraquinone derivative emodin. As the main component of Hypericum perforatum, it has traditionally been used throughout the history of folk medicine. In the last three decades, hypericin has also become the subject of intensive biochemical research and is proving to be a multifunctional agent in drug and medicinal applications. Recent studies report antidepressive, antineoplastic, antitumor and antiviral (human immunodeficiency and hepatitis C virus) activities of hypericin; intriguing information even if confirmation of data is incomplete and mechanisms of these activities still remain largely unexplained. In other contemporary studies, screening hypericin for inhibitory effects on various pharmaceutically important enzymes such as MAO (monoaminoxidase), PKC (protein kinase C), dopamine-beta-hydroxylase, reverse transcriptase, telomerase and CYP (cytochrome P450), has yielded results supporting therapeutic potential. Research of hypericin and its effect on GABA-activated (gamma amino butyric acid) currents and NMDA (N-methyl-D-aspartat) receptors also indicate the therapeutic potential of this substance whereby new insights in stroke research (apoplexy) are expected. Also in the relatively newly established fields of medical photochemistry and photobiology, intensive research reveals hypericin to be a promising novel therapeutic and diagnostic agent in treatment and detection of cancer (photodynamic activation of free radical production). Hypericin is not new to the research community, but it is achieving a new and promising status as an effective agent in medical diagnostic and therapeutic applications. New, although controversial data, over the recent years dictate further research, re-evaluation and discussion of this substance. Our up-to-date summary of hypericin, its activities and potentials, is aimed to contribute to this process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
O’Connor, A. E., Gallagher, W. M., & Byrne, A. T. (2009) · Photochemistry and Photobiology · doi:10.1111/j.1751-1097.2009.00585.x · Cited by 1,191
Antimicrobial Photodynamic Therapy to Kill Gram-negative Bacteria
Sperandio, F. F., Huang, Y.-Y., & Hamblin, M. R. (2014) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/1574891x113089990012 · Cited by 585
An updated overview on the development of new photosensitizers for anticancer photodynamic therapy
Zhang, J., Jiang, C., Figueiró Longo, J. P., Azevedo, R. B., Zhang, H., & Muehlmann, L. A. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.09.003 · Cited by 574
Nanotechnology-Based Drug Delivery Systems for Photodynamic Therapy of Cancer: A Review
Calixto, G., Bernegossi, J., De Freitas, L., Fontana, C., & Chorilli, M. (2016) · Molecules · doi:10.3390/molecules21030342 · Cited by 538
Anticancer compounds derived from fungal endophytes: their importance and future challenges
Kharwar, R. N., Mishra, A., Gond, S. K., Stierle, A., & Stierle, D. (2011) · Natural Product Reports · doi:10.1039/c1np00008j · Cited by 530
Metadata
- Authors
- Kubin, A., Wierrani, F., Burner, U., Alth, G., & Grunberger, W.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2005-01-01
- Volume
- 11
- Issue
- 2
- Pages
- 233-253
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2153563295
- Cited by
- 246
- References
- 0
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypericin - The Facts About a Controversial Agent. https://app.cochat.ai/papers/10.2174/1381612053382287
- The paper
- Kubin, A., Wierrani, F., Burner, U., Alth, G., & Grunberger, W. (2005). Hypericin - The Facts About a Controversial Agent. Current Pharmaceutical Design. https://doi.org/10.2174/1381612053382287
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.